The stock is a binary event play on izicopan Phase 2 data in AAV and renal diseases, with no near-term revenue catalysts. Monitor trial initiation (late 2026/early 2027) and any partnership announcements for HS/CSU. The cash runway through 2029 removes near-term financing risk but the massive dilution from the May offering caps upside until clinical proof-of-concept.
Price Chart
Executive Summary
InflaRx reported H1 2026 results with a net loss of €16.2M (improved from €22.7M YoY) and zero revenue after discontinuing GOHIBIC sales. The company raised ~$140M net in a May 2026 offering, extending its cash runway into 2029 to fund izicopan Phase 2 development in AAV and renal diseases. The filing is neutral — the improved loss is from cost-cutting, not revenue growth, and the cash raise funds a high-risk pipeline pivot with no near-term catalysts.
Key Facts
- Net loss for H1 2026 was €16.2M ($0.17/share), improved from €22.7M ($0.35/share) in H1 2025.
- Revenue was zero in H1 2026 vs. €39,432 in H1 2025, due to discontinuation of GOHIBIC sales in Dec 2025.
- Cash, cash equivalents and marketable securities totaled €158.4M as of June 30, 2026, up from €16.0M at Dec 31, 2025.
- In May 2026, the company completed a registered direct offering of 75M shares at $2.00/share, raising net proceeds of €119.3M ($140.4M).
- Phase 2 trial for izicopan in AAV is planned for late 2026 or early 2027; proof-of-concept studies in aHUS, IgAN, and C3G are targeted for 2027.
- FDA terminated the EUA for GOHIBIC (vilobelimab), effective July 1, 2027.
- Research and development expenses decreased 37% YoY to €8.9M in H1 2026, driven by lower third-party costs and reduced share-based compensation.
- The company believes existing funds will support operations into the end of 2029.
Financial Impact
No revenue; net loss improved by €6.5M YoY to €16.2M; cash position strengthened by ~€130M to €158.4M via a $150M equity offering.
Risk Factors
- izicopan Phase 2 trials in AAV and renal diseases may fail to meet endpoints, destroying pipeline value.
- Massive shareholder dilution from the 75M-share May 2026 offering (more than doubling shares outstanding) will pressure EPS and stock price.
- Zero revenue and reliance on equity financing; if izicopan fails, the company may need to raise additional capital at distressed terms.
- FDA EUA termination for GOHIBIC effective July 2027 eliminates any remaining commercial optionality for vilobelimab in COVID-19.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001140361-26-031540 |
| Document: ef20079015_ex99-2.htm | 0001140361-26-031540 |
| Document: ef20079015_ex99-3.htm | 0001140361-26-031540 |
| Document: ef20079015_6k.htm | 0001140361-26-031540 |
| Document: 0001140361-26-031540-index-headers.html | 0001140361-26-031540 |
| Document: 0001140361-26-031540-index.html | 0001140361-26-031540 |
| Document: 0001140361-26-031540.txt | 0001140361-26-031540 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $1.56 | awaiting T+20 | — | $1.58 (+0.96%) |
Oct 22, 2026 4d ago | Press Release | $1.53 | awaiting T+20 | — | $1.58 (+2.94%) |
Oct 2, 2026 24d ago | Press Release | $1.72 | awaiting T+20 | — | $1.58 (−8.43%) |
Oct 1, 2026 25d ago | Press Release | $1.71 | awaiting T+20 | — | $1.58 (−7.89%) |
Aug 14, 2026 10w ago | 424B5 | $2.07 $2.02 | ▲ +2.42% | ▲ +0.44% | $1.58 (+23.91%) |
Aug 13, 2026 10w ago | EFFECT | $2.01 $2.09 | ▼ −3.98% | ▼ −5.73% | $1.58 (+21.64%) |
Aug 6, 2026 11w ago | 6-K | $1.72 $2.23 | ▲ +29.65% | ▲ +29.05% | $1.58 (−8.43%) |
Jun 30, 2026 16w ago | 6-K | $2.33 $1.65 | ▼ −29.18% | ▼ −27.00% | $1.58 (−32.40%) |
Jun 30, 2026 16w ago | Press Release | $2.24 $1.70 | ▼ −24.11% | ▼ −23.08% | $1.58 (−29.69%) |
May 6, 2026 24w ago | 424B5 | $2.65 $2.06 | ▲ +22.26% | ▲ +25.40% | $1.58 (+40.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers